- Home
- EYPT vs NWBI Comparison
EYPT vs NWBI Comparison
Compare EYPT & NWBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EYPT | NWBI |
|---|---|---|
| Founded | 1987 | 1896 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Major Banks |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.8B |
| IPO Year | 2005 | 2009 |
Fundamental Metrics
Financial Performance| Metric | EYPT | NWBI |
|---|---|---|
| Price | $18.29 | $12.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $28.75 | $13.67 |
| AVG Volume (30 Days) | ★ 1.6M | 955.6K |
| Earning Date | 03-23-2026 | 04-27-2026 |
| Dividend Yield | N/A | ★ 6.43% |
| EPS Growth | N/A | ★ 16.46 |
| EPS | N/A | ★ 0.92 |
| Revenue | ★ $7,539,000.00 | N/A |
| Revenue This Year | N/A | $5.41 |
| Revenue Next Year | N/A | $6.67 |
| P/E Ratio | ★ N/A | $13.51 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.91 | $10.75 |
| 52 Week High | $19.11 | $13.62 |
Technical Indicators
Market Signals| Indicator | EYPT | NWBI |
|---|---|---|
| Relative Strength Index (RSI) | 67.28 | 46.09 |
| Support Level | $11.88 | $12.57 |
| Resistance Level | $19.06 | $12.92 |
| Average True Range (ATR) | 1.27 | 0.34 |
| MACD | 0.54 | -0.07 |
| Stochastic Oscillator | 90.58 | 38.11 |
Price Performance
Historical ComparisonAbout EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
About NWBI Northwest Bancshares Inc.
Northwest Bancshares Inc is a stockholding company for Northwest Bank. Northwest Bank is a stock savings bank and a community-oriented financial institution offering personal and commercial banking business solutions, investment management, trust services, and insurance products. It also offers consumer finance loans through a wholly-owned subsidiary. The bank's loan portfolio segment consists of personal banking and business banking loans. Personal banking includes residential mortgages, home equity loans, and other consumer loans. Business banking loans consist of commercial real estate loans and commercial loans. Net interest income is the company's primary contributor to revenue.